Recombinant Human Fc Receptor-Like Protein 4 (FCRL4) Protein (His-SUMO)

Name: Recombinant Human Fc Receptor-Like Protein 4 (FCRL4) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-09516P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: Fc receptors, Featured fc receptors molecules, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Fc Receptor-Like Protein 4 (FCRL4) Protein (His-SUMO) is produced by our E.coli expression system. This is a extracellular protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q96PJ5
Target Symbol	FCRL4
Synonyms	CD307d; Fc receptor homolog 4; Fc receptor like 4; Fc receptor like protein 4; Fc receptor-like protein 4; FcR like protein 4; FcR-like protein 4; FcRH4; FcRL4; FCRL4_HUMAN; hIFGP2; IFGP family protein 2; IGFP2; Immune receptor translocation associated protein 1; Immune receptor translocation-associated protein 1; Immunoglobulin superfamily receptor translocation associated 1; Immunoglobulin superfamily receptor translocation associated gene 1; IRTA1
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	AHKPVISVHPPWTTFFKGERVTLTCNGFQFYATEKTTWYHRHYWGEKLTLTPGNTLEVRESGLYRCQARGSPRSNPVRLLFSSDSLILQAPYSVFEGDTLVLRCHRRRKEKLTAVKYTWNGNILSISNKSWDLLIPQASSNNNGNYRCIGYGDENDVFRSNFKIIKIQELFPHPELKATDSQPTEGNSVNLSCETQLPPERSDTPLHFNFFRDGEVILSDWSTYPELQLPTVWRENSGSYWCGAETVRGNIHKHSPSLQIHVQRIPVSGVLLETQPSGGQAVEGEMLVLVCSVAEGTGDTTFSWHREDMQESLGRKTQRSLRAELELPAIRQSHAGGYYCTADNSYGPVQSMVLNVTVRETPGNRDGL
Expression Range	20-387aa
Protein Length	Extracellular Domain
Mol. Weight	57.6kDa
Research Area	Immunology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	May function as an inhibitor of the B-cell receptor signaling. May function in the B-cell-mediated immune response.
Subcellular Location	Cell membrane; Single-pass type I membrane protein.
Database References	HGNC: 18507 OMIM: 605876 KEGG: hsa:83417 STRING: 9606.ENSP00000271532 UniGene: Hs.120260
Associated Diseases	A chromosomal aberration involving FCRL4 is found in non-Hodgkin lymphoma (NHG). Translocation t(1;1)(p36.3; q21.1-2).
Tissue Specificity	Specifically expressed by memory and monocytoid B-cells which populate spleen and lymph nodes. Preferentially expressed in memory B-cells associated with mucosal tissue (at protein level).

Gene Functions References

We conclude that these activated B cells are a component of the local autoimmune response, and through their RANKL expression, can contribute to joint destruction. Furthermore, their expression of FcRL4 and their enrichment in the IgA isotype points towards a potential role for these cells in the link between mucosal and joint inflammation. PMID: 28343748
intraepithelial FcRL4(+) B-cells are present in the salivary glands of pSS patients. These cells are likely involved in the epithelial changes seen in pSS. Their enrichment in parotid glands may explain why MALT lymphomas in pSS patients preferentially develop at this specific location. PMID: 28390747
Commercially available IRTA1 antibody can immunohistochemically distinguish MALT lymphoma from other low-grade B-cell lymphomas. PMID: 27666766
Significantly increased FCRL4 mRNA only in Graves disease patients but not in Hashimoto patients compared to normal controls. PMID: 25738996
The observed significant gene-environment interaction suggests that drinking and cooking oil use with FCRL4 gene polymorphism has a significant interaction. PMID: 25012527
we provide evidence for involvement of HCK and FGR in FCRL4-mediated immunoregulation and for the functional importance of posttranslational modifications of the FCRL4 molecule. PMID: 25972488
IRTA1 and T-bet are positive markers for the diagnosis of nodal marginal zone lymphoma PMID: 23855758
Data indicate that signaling by HIV-1 gp120 through integrin alpha4beta7 resulted in increased expression of the immunosuppressive cytokine TGF-beta1 and FcRL4. PMID: 24162774
The cytological features, growth pattern and IRTA1 positivity in nodal marginal zone lymphomas suggest they may derive from IRTA1(+) perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. PMID: 22716304
The FCRL4 polymorphisms may play an important role in the susceptibility and severity of ankylosing spondylitis in the Chinese Han population. PMID: 22777505
In cellular binding assays, as a bona fide receptor FcRL4 binds efficiently to immunoglobulin (Ig)A. PMID: 22491254
Data suggest that expression of FcRL4 in B-cells results in inhibition of BCR signaling at point of Syk phosphorylation by mechanism that involves phosphorylation of FcRL4 and its association with SHP-1/SHP-2. PMID: 21908428
role of IRTA1 in the immune function of B cells within epithelia PMID: 12881317
Monocytoid B cells differ in their antigen profile (presence of IRTA1) from splenic and nodal marginal zone B cells. PMID: 16079106
Cell surface expression of this immunoregulatory molecule is restricted to a subpopulation of memory B cells. PMID: 16157685
Down-regulation of FCRL4 is associated with acute lymphoblastic leukemia. PMID: 18802695
FCRL4 is located on atypical memory B cells population significantly expanded in Plasmodium falciparum-exposed Malian adults and children PMID: 19592645

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.